The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative

Expert Review of Vaccines

Volumn 12, Issue 8, 2013, Pages 903-915

  Sáfadi, Marco Aurélio P ^a   De Los Monteros, Luz Elena Espinosa ^a   López, Eduardo Luis ^a   Sàez Llorens, Xavier ^a   Lemos, Ana Paula ^a   Moreno Espinosa, Sarbelio ^a   Ayala, Silvia González ^a   Torres, Juan Pablo ^a   De Moraes, José Cassio ^a   Vázquez, Julio Alberto ^a  

^a Division of Infectious Diseases   (Brazil)

Author keywords

case definition; control; epidemiology; Global Meningococcal Initiative; Latin America; management; meningococcal disease; PCR; surveillance; vaccination

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

BACTERIUM ISOLATE; CENTRAL AMERICA; DECISION MAKING; EDUCATION PROGRAM; EPIDEMIC; GEOGRAPHIC DISTRIBUTION; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; MENINGOCOCCEMIA; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOUTH AMERICA; VACCINATION;

COMMUNICABLE DISEASE CONTROL; HUMANS; LATIN AMERICA; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; PREVALENCE;

EID: 84887743825     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.814879     Document Type: Review

References (57)

1. Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Vaccines. Plotkin SA, Orenstein WA, Offit PA (Eds). Fifth Edition. WB Saunders, Philadelphia, PA, USA, 399-434 (2008
2. Harrison LH, Pelton SI, Wilder-Smith A et al. The Global Meningococcal Initiative: Recommendations for reducing the global burden of meningococcal disease. Vaccine 29(18), 3363-3371 (2011
3. Sáfadi MA, Cintra OA. Epidemiology of meningococcal disease in Latin America: Current situation and opportunities for prevention. Neurol. Res. 32(3), 263-271 (2010
4. Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recomm. Rep. 54(RR-7), 1-21 (2005
5. National Advisory Committee on Immunization. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). Can. Commun. Dis. Rep. 35(ACS-3), 1-40 (2009
6. Cohn AC, MacNeil JR, Harrison LH et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: Implications for prevention of meningococcal disease. Clin. Infect. Dis. 50(2), 184-191 (2010
7. Cordeiro SM, Neves AB, Ribeiro CT et al. Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil. Trans. R. Soc. Trop. Med. Hyg. 101(11), 1147-1153 (2007
8. Inés Agudelo C, Sanabria OM, Ovalle MV. Serogroup Y meningococcal disease, Colombia. Emerging Infect. Dis. 14(6), 990-991 (2008
9. Nieto-Guevara J, Luciani K, Montesdeoca- Melían A, Mateos-Durán M. Epidemiology of meningococcal disease in the Panamanian pediatric population, 1998-2008. J. Infect. Dev. Ctries. 5(5), 318-323 (2011
10. Abad R, Agudelo CI, Brandileone MC et al. Molecular characterization of invasive serogroup Y Neisseria meningitidis strains isolated in the Latin America region. J. Infect. 59(2), 104-114 (2009
11. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 62(RR-2), 1-22 (2013
12. Sáfadi MA, McIntosh ED. Epidemiology and prevention of meningococcal disease: A critical appraisal of vaccine policies. Expert Rev. Vaccines 10(12), 1717-1730 (2011
13. Kimmel SR. Prevention of meningococcal disease. Am. Fam. Physician 72(10), 2049-2056 (2005
14. Stephens DS. Conquering the meningococcus. FEMS Microbiol. Rev. 31(1), 3-14 (2007
15. Panatto D, Amicizia D, Lai PL, Gasparini R. Neisseria meningitidis B vaccines. Expert Rev. Vaccines 10(9), 1337-1351 (2011
16. Gossger N, Snape MD, Yu LM et al.; European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: A randomized controlled trial. JAMA 307(6), 573-582 (2012
17. Richmond PC, Marshall HS, Nissen MD et al.; 2001 Study Investigators. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, Phase 2 trial. Lancet Infect. Dis. 12(8), 597-607 (2012
18. Santolaya ME, O'Ryan ML, Valenzuela MT et al.; V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: A Phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 379(9816), 617-624 (2012
19. Sáfadi MA, González-Ayala S, Jäkel A, Wieffer H, Moreno C, Vyse A. The epidemiology of meningococcal disease in Latin America 1945-2010: An unpredictable and changing landscape. Epidemiol. Infect. 1-12 (2012
20. Ibarz-Pavón AB, Lemos AP, Gorla MC, Regueira M, Gabastou JM; SIREVA Working Group II. Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006-2010. PLoS ONE 7(8), e44102 (2012
21. Sacchi CT, Fukasawa LO, Gonçalves MG et al.; São Paulo RT-PCR Surveillance Project Team. Incorporation of real-time PCR into routine public health surveillance of culture negative bacterial meningitis in São Paulo, Brazil. PLoS ONE 6(6), e20675 (2011
22. Chacon-Cruz E, Sugerman DE, Ginsberg MM et al. Surveillance for invasive meningococcal disease in children, US-Mexico border, 2005-2008. Emerging Infect. Dis. 17(3), 543-546 (2011
23. Espinosa de los Monteros LE, Jimenez- Rojas LV, Matias San Juan NA, Gomez- Barreto D. Grupo Mexicano de Trabajo en Enfermedad Meningococcica. Unusual increase in meningococcal disease associated with serogroup C in Mexico City. 7th World Congress on Pediatric Infectious Diseases (WSPID), 16-19 November 2011.
24. Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J. Clin. Microbiol. 44(1), 124-131 (2006
25. Efron AM, Sorhouet C, Salcedo C, Abad R, Regueira M, Vázquez JA. W135 invasive meningococcal strains spreading in South America: Significant increase in incidence rate in Argentina. J. Clin. Microbiol. 47(6), 1979-1980 (2009
26. Safadi MA, Liphaus B, Okay MIG, Yu ALF, Ribeiro AF, Carvalhanas TRMP. Early impact of meningococcal C conjugate vaccination program on disease trends in Sao Paulo, Brazil. Presented at: European Society for Paediatrics Infectious Diseases, Thessaloniki, Greece, 8-12 May 2012.
27. Caugant DA, Maiden MC. Meningococcal carriage and disease-population biology and evolution. Vaccine 27(Suppl. 2), B64-B70 (2009
28. Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba. NIPH Ann. 14(2), 195-207; discussion 208 (1991
29. Climent Y, Yero D, Martinez I et al. Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba. J. Clin. Microbiol. 48(3), 802-810 (2010
30. De Soarez PC, Sartori AM, de Andrade Lagoa Nóbrega L, Itria A, Novaes HM. Cost-effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil. Value Health 14(8), 1019-1027 (2011
31. Kaninda AV, Belanger F, Lewis R et al. Effectiveness of incidence thresholds for detection and control of meningococcal meningitis epidemics in northern Togo. Int. J. Epidemiol. 29(5), 933-940 (2000
32. Iser BP, Lima HC, de Moraes C et al. Outbreak of Neisseria meningitidis C in workers at a large food-processing plant in Brazil: Challenges of controlling disease spread to the larger community. Epidemiol. Infect. 140(5), 906-915 (2012
33. Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: A persistent problem with an imminent solution. Vaccine 27(Suppl. 2), B13-B19 (2009
34. Saliou P, Debois H. Which vaccination strategies for African meningococcal meningitis?. Bull. Soc. Pathol. Exot. 95(5), 326-330 (2002
35. Parent du Chatelet I, Gessner BD, da SA. Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: A theoretical modeling analysis. Vaccine 19(25-26), 3420-3431 (2001
36. Drew RJ, Ó Maoldomhnaigh C, Gavin PJ, O'Sullivan N, Butler KM, Cafferkey M. The impact of meningococcal polymerase chain reaction testing on laboratory confirmation of invasive meningococcal disease. Pediatr. Infect. Dis. J. 31(3), 316-318 (2012
37. Dolan Thomas J, Hatcher CP, Satterfield DA et al. sodC-based real-time PCR for detection of Neisseria meningitidis. PLoS ONE 6(5), e19361 (2011
38. Van Gastel E, Bruynseels P, Verstrepen W, Mertens A. Evaluation of a real-time polymerase chain reaction assay for the diagnosis of pneumococcal and meningococcal meningitis in a tertiary care hospital. Eur. J. Clin. Microbiol. Infect. Dis. 26(9), 651-653 (2007
39. Bryant PA, Li HY, Zaia A et al. Prospective study of a real-time PCR that is highly sensitive, specific, and clinically useful for diagnosis of meningococcal disease in children. J. Clin. Microbiol. 42(7), 2919-2925 (2004
40. Wang X, Theodore MJ, Mair R et al. Clinical validation of multiplex real-time PCR assays for detection of bacterial meningitis pathogens. J. Clin. Microbiol. 50(3), 702-708 (2012
41. Corless CE, Guiver M, Borrow R, Edwards-Jones V, Fox AJ, Kaczmarski EB. Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae in suspected cases of meningitis and septicemia using real-time PCR. J. Clin. Microbiol. 39(4), 1553-1558 (2001
42. Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J. Infect. Dis. 178(3), 870-874 (1998
43. MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: A randomized controlled trial. JAMA 280(19), 1685-1689 (1998
44. Al Mazrou Y, Khalil M, Bravo C et al. Meningococcal conjugate vs meningococcal polysaccharide vaccine in Saudi Arabia adolescents previously vaccinated with multiple doses of meningococcal polysaccharide vaccine. Presented at: European Meningococcal Disease Society (EMGM) Congress. Manchester, UK, 17-19 June 2009.
45. Gray SJ, Trotter CL, Ramsay ME et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: Contribution and experiences of the Meningococcal Reference Unit. J. Med. Microbiol. 55(Pt 7), 887-896 (2006
46. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: Lessons learned from serogroup C conjugate vaccination programs. Expert Rev. Vaccines 8(7), 851-861 (2009
47. Perrett KP, Winter AP, Kibwana E et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: A Phase 4 clinical trial. Clin. Infect. Dis. 50(12), 1601-1610 (2010
48. Espín Ríos I, García-Fulgueíras A, Navarro Alonso JA et al. Seroconversion and duration of immunity after vaccination against group C meningococcal infection in young children. Vaccine 18(24), 2656-2660 (2000
49. Granoff DM, Morgan A, Welsch JA. Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidisdiphtheria toxoid conjugate vaccine. Pediatr. Infect. Dis. J. 24(2), 132-136 (2005
50. Khatami A, Snape MD, Davis E et al. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine 30(18), 2831-2838 (2012
51. Borrow R, Goldblatt D, Andrews N et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J. Infect. Dis. 186(9), 1353-1357 (2002
52. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364(9431), 365-367 (2004
53. Neto RB, Jayaraman K. Brazil and India access pharma vaccine know-how. Nat. Biotechnol. 27(12), 1063-1064 (2009
54. Milstien JB, Gaulé P, Kaddar M. Access to vaccine technologies in developing countries: Brazil and India. Vaccine 25(44), 7610-7619 (2007
55. de Oliveira LH, Danovaro-Holliday MC, Sanwogou NJ, Ruiz-Matus C, Tambini G, Andrus JK. Progress in the introduction of the rotavirus vaccine in Latin America and the Caribbean: Four years of accumulated experience. Pediatr. Infect. Dis. J. 30(Suppl. 1), S61-S66 (2011
56. John TJ, Gupta S, Chitkara AJ, Dutta AK, Borrow R. An overview of meningococcal disease in India: Knowledge gaps and potential solutions. Vaccine 31(25), 2731-2737 (2013
57. Ulloa-Gutierrez R, Miño G, Odio C, Avila-Aguero ML, Brea J. Vaccine-preventable diseases and their impact on Latin American children. Expert Rev. Vaccines 10(12), 1671-1673 (2011